Description: MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Home Page: mirapharmaceuticals.com
1200 Brickell Avenue
Miami,
FL
32183
United States
Phone:
786-432-9792
Officers
| Name | Title |
|---|---|
| Mr. Erez Aminov | CEO & Chairman |
| Ms. Michelle Yanez M.B.A. | CFO, Secretary & Treasurer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.1901 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-08-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |